BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 16973579)

  • 1. Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins.
    Anderson JL; Campbell EM; Wu X; Vandegraaff N; Engelman A; Hope TJ
    J Virol; 2006 Oct; 80(19):9754-60. PubMed ID: 16973579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fates of retroviral core components during unrestricted and TRIM5-restricted infection.
    Kutluay SB; Perez-Caballero D; Bieniasz PD
    PLoS Pathog; 2013 Mar; 9(3):e1003214. PubMed ID: 23505372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. General Model for Retroviral Capsid Pattern Recognition by TRIM5 Proteins.
    Wagner JM; Christensen DE; Bhattacharya A; Dawidziak DM; Roganowicz MD; Wan Y; Pumroy RA; Demeler B; Ivanov DN; Ganser-Pornillos BK; Sundquist WI; Pornillos O
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29187540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection.
    Wu X; Anderson JL; Campbell EM; Joseph AM; Hope TJ
    Proc Natl Acad Sci U S A; 2006 May; 103(19):7465-70. PubMed ID: 16648264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophilin A protects HIV-1 from restriction by human TRIM5α.
    Kim K; Dauphin A; Komurlu S; McCauley SM; Yurkovetskiy L; Carbone C; Diehl WE; Strambio-De-Castillia C; Campbell EM; Luban J
    Nat Microbiol; 2019 Dec; 4(12):2044-2051. PubMed ID: 31636416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRIM5α Degradation via Autophagy Is Not Required for Retroviral Restriction.
    Imam S; Talley S; Nelson RS; Dharan A; O'Connor C; Hope TJ; Campbell EM
    J Virol; 2016 Jan; 90(7):3400-10. PubMed ID: 26764007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasomal degradation of TRIM5alpha during retrovirus restriction.
    Rold CJ; Aiken C
    PLoS Pathog; 2008 May; 4(5):e1000074. PubMed ID: 18497858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient transduction of human hematopoietic repopulating cells with a chimeric HIV1-based vector including SIV capsid.
    Uchida N; Hsieh MM; Washington KN; Tisdale JF
    Exp Hematol; 2013 Sep; 41(9):779-788.e1. PubMed ID: 23665451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity.
    Keckesova Z; Ylinen LM; Towers GJ
    J Virol; 2006 May; 80(10):4683-90. PubMed ID: 16641261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent insights into the mechanism and consequences of TRIM5α retroviral restriction.
    Sastri J; Campbell EM
    AIDS Res Hum Retroviruses; 2011 Mar; 27(3):231-8. PubMed ID: 21247355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoproteasome activation enables human TRIM5α restriction of HIV-1.
    Jimenez-Guardeño JM; Apolonia L; Betancor G; Malim MH
    Nat Microbiol; 2019 Jun; 4(6):933-940. PubMed ID: 30886358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity.
    Perez-Caballero D; Hatziioannou T; Zhang F; Cowan S; Bieniasz PD
    J Virol; 2005 Dec; 79(24):15567-72. PubMed ID: 16306627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implication of TRIM alpha and TRIMCyp in interferon-induced anti-retroviral restriction activities.
    Carthagena L; Parise MC; Ringeard M; Chelbi-Alix MK; Hazan U; Nisole S
    Retrovirology; 2008 Jul; 5():59. PubMed ID: 18613956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophilin A potentiates TRIM5α inhibition of HIV-1 nuclear import without promoting TRIM5α binding to the viral capsid.
    Burse M; Shi J; Aiken C
    PLoS One; 2017; 12(8):e0182298. PubMed ID: 28767697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Both TRIM5alpha and TRIMCyp have only weak antiviral activity in canine D17 cells.
    Bérubé J; Bouchard A; Berthoux L
    Retrovirology; 2007 Sep; 4():68. PubMed ID: 17892575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIM5α and Species Tropism of HIV/SIV.
    Nakayama EE; Shioda T
    Front Microbiol; 2012; 3():13. PubMed ID: 22291694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha.
    Campbell EM; Perez O; Anderson JL; Hope TJ
    J Cell Biol; 2008 Feb; 180(3):549-61. PubMed ID: 18250195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional evidence for the involvement of microtubules and dynein motor complexes in TRIM5α-mediated restriction of retroviruses.
    Pawlica P; Le Sage V; Poccardi N; Tremblay MJ; Mouland AJ; Berthoux L
    J Virol; 2014 May; 88(10):5661-76. PubMed ID: 24600008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIM5 Retroviral Restriction Activity Correlates with the Ability To Induce Innate Immune Signaling.
    Lascano J; Uchil PD; Mothes W; Luban J
    J Virol; 2016 Jan; 90(1):308-16. PubMed ID: 26468522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independent evolution of an antiviral TRIMCyp in rhesus macaques.
    Wilson SJ; Webb BL; Ylinen LM; Verschoor E; Heeney JL; Towers GJ
    Proc Natl Acad Sci U S A; 2008 Mar; 105(9):3557-62. PubMed ID: 18287035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.